Vistagen Therapeutics, Inc. (VTGN) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2026, Vistagen Therapeutics reported revenue of $1.3M, up 161.1% from $486,000 the year before. Net income was -$69.7M (a -5491.3% net margin), or -$1.83 per diluted share. Operating margin was -5683.7%. Operating activities generated -$66.4M of cash, leaving -$66.4M of free cash flow. At fiscal year end, Vistagen Therapeutics held $48.6M in total assets against $13.0M in total liabilities, including $30.8M of cash and equivalents.
Open the full interactive Vistagen Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Vistagen Therapeutics Key Stats
| Share Price | $0.21 |
|---|---|
| Market Cap | $9.0M |
| Revenue YoY Growth | +161.1% |
| 52-Week Range | $0.21 – $4.90 |
| Shares Outstanding | 43.0 million (basic, 2027 Q1) |
Vistagen Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1M | $1.1M | -$227,000 | $1.1M | $486,000 | $1.3M |
| Operating Income | -$17.9M | -$47.8M | -$59.3M | -$33.0M | -$56.0M | -$72.1M |
| Pre-Tax Income | -$17.9M | -$47.8M | -$59.2M | -$29.4M | -$51.4M | -$69.7M |
| Income Tax | $2,600 | $3,400 | $5,900 | $4,000 | $7,000 | $7,000 |
| Net Income | -$17.9M | -$47.8M | -$59.2M | -$29.4M | -$51.4M | -$69.7M |
| Diluted EPS | -$14.70 | — | — | -$1.52 | -$1.67 | -$1.83 |
Vistagen Therapeutics Quarterly Results
| 2026 Q2 | 2026 Q3 | 2026 Q4 | 2027 Q1 | |
|---|---|---|---|---|
| Revenue | $258,000 | $303,000 | $464,000 | $1.5M |
| Net Income | -$19.4M | -$18.9M | -$16.3M | -$13.0M |
| Diluted EPS | -$0.54 | -$0.45 | -$0.43 | -$0.30 |
Vistagen Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $103.1M | $68.1M | $16.6M | $119.2M | $67.1M | $30.8M |
| Current Assets | $104.1M | $71.0M | $17.5M | $120.7M | $82.1M | $46.9M |
| Total Assets | $108.3M | $74.6M | $21.1M | $123.7M | $84.3M | $48.6M |
| Current Liabilities | $4.2M | $5.8M | $4.6M | $5.1M | $12.6M | $12.8M |
| Total Long-Term Debt | — | — | — | — | — | $96,000 |
| Total Liabilities | $16.3M | $9.9M | $9.0M | $9.4M | $14.0M | $13.0M |
| Shareholders' Equity | $92.0M | $64.7M | $12.1M | $114.3M | $70.4M | $35.5M |
Vistagen Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$12.1M | -$45.3M | -$49.7M | -$25.8M | -$42.1M | -$66.4M |
| Cash From Investing | -$275,400 | -$200,400 | -$740,300 | -$61,000 | -$13.1M | -$877,000 |
| Cash From Financing | $114.1M | $10.5M | -$1.0M | $128.4M | $3.2M | $31.0M |
| Free Cash Flow | -$12.3M | -$45.5M | -$50.2M | -$25.8M | -$42.1M | -$66.4M |
Figures from Vistagen Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Vistagen Therapeutics financials page for every line item.
Vistagen Therapeutics Company Profile
| Ticker | VTGN |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | South San Francisco, California |
| Incorporated in | Nevada |
| Fiscal Year End | March 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001411685 |
Frequently Asked Questions
What was Vistagen Therapeutics' revenue in fiscal 2026?
Vistagen Therapeutics (VTGN) reported revenue of $1.3M for fiscal 2026.
What is Vistagen Therapeutics' annual revenue history?
Vistagen Therapeutics' annual revenue by fiscal year: 2021: $1.1M; 2022: $1.1M; 2023: -$227,000; 2024: $1.1M; 2025: $486,000; 2026: $1.3M.
What was Vistagen Therapeutics' net income in fiscal 2026?
Vistagen Therapeutics reported net income of -$69.7M for fiscal 2026.
What was Vistagen Therapeutics' earnings per share (EPS) in fiscal 2026?
Vistagen Therapeutics' diluted EPS was -$1.83 for fiscal 2026 (adjusted for any later stock splits).
How much free cash flow did Vistagen Therapeutics generate in fiscal 2026?
Vistagen Therapeutics generated -$66.4M of free cash flow in fiscal 2026.
What was Vistagen Therapeutics' revenue last quarter?
In its most recent reported quarter (2027 Q1), Vistagen Therapeutics reported revenue of $1.5M.
How much debt does Vistagen Therapeutics have?
Vistagen Therapeutics reported $96,000 of long-term debt, including the current portion, at the end of fiscal 2026.
How many shares of Vistagen Therapeutics are outstanding?
Vistagen Therapeutics reported a weighted average of 43.0 million basic shares outstanding in 2027 Q1.
What is Vistagen Therapeutics' market cap?
Based on its latest closing price, Vistagen Therapeutics (VTGN) has a market capitalization of about $9.0M.
When does Vistagen Therapeutics' fiscal year end?
Vistagen Therapeutics' fiscal year end, as registered with the SEC, is March 31.
Where is Vistagen Therapeutics headquartered?
Vistagen Therapeutics lists its business address in South San Francisco, California in its SEC filings.